The present application discloses a solid beverage for conditioning blood stasis constitution. The solid beverage comprises the following components in parts by weight: 21-55 parts of hawthorn, 9-33 parts of peach seed, 9-33 parts of gingko, 5-21 parts of platycodon grandiflorus, 9-33 parts of dried tangerine peel, 0.5-4 parts of cinnamon, 9-33 parts of the root of kudzu vine, 2-21 parts of dahurian angelica, 10-29 parts of dextrin, 7-25 parts of maltodextrin, 8-26 parts of soluble starch and 0.05-0.2 parts of aspartame. The solid beverage of the present application is simple and convenient to prepare, the raw materials used are all medicinal materials with dual-purpose of drug and food, and the auxiliary materials used also meet the national standard GB2760-2011 (the National Food Safety Standard for Food Additive Use). Thus, the solid beverage is safe to consume and good in taste, and has certain effects on the improvement of blood stasis constitution, and the production process thereof is suitable for industrial mass production.

The present application discloses a solid beverage for conditioning blood stasis constitution. The solid beverage comprises the following components in parts by weight: 21-55 parts of hawthorn, 9-33 parts of peach seed, 9-33 parts of gingko, 5-21 parts of platycodon grandiflorus, 9-33 parts of dried tangerine peel, 0.5-4 parts of cinnamon, 9-33 parts of the root of kudzu vine, 2-21 parts of dahurian angelica, 10-29 parts of dextrin, 7-25 parts of maltodextrin, 8-26 parts of soluble starch and 0.05-0.2 parts of aspartame. The solid beverage of the present application is simple and convenient to prepare, the raw materials used are all medicinal materials with dual-purpose of drug and food, and the auxiliary materials used also meet the national standard GB2760-2011 (the National Food Safety Standard for Food Additive Use). Thus, the solid beverage is safe to consume and good in taste, and has certain effects on the improvement of blood stasis constitution, and the production process thereof is suitable for industrial mass production.

The present disclosure provides a traditional Chinese medicine (TCM) composition for preventing and treating diabetes, a TCM preparation and use thereof, and belongs to the technical field of medicine. The TCM composition includes the following raw materials: 3-20 parts by weight of Rhizoma Coptidis, 9-24 parts by weight of Rhizoma Atractylodis, 6-24 parts by weight of Feculae Bombycis, 10-60 parts by weight of Stigma Maydis, 10-60 parts by weight of Radix Trichosanthis, 6-30 parts by weight of Radix Scrophulariae, 10-60 parts by weight of Radix et Rhizoma Salviae Miltiorrhizae, and 10-50 parts by weight of Fructus Crataegi Preparata. In the TCM composition provided by the present disclosure, all medicinal materials are synergistic to achieve the effects of clearing heat, drying dampness, fortifying the spleen, dispersing blood stasis, dispersing accumulations, lowering lipids, nourishing yin and moistening dryness.

The present disclosure provides a traditional Chinese medicine (TCM) composition for preventing and treating diabetes, a TCM preparation and use thereof, and belongs to the technical field of medicine. The TCM composition includes the following raw materials: 3-20 parts by weight of Rhizoma Coptidis, 9-24 parts by weight of Rhizoma Atractylodis, 6-24 parts by weight of Feculae Bombycis, 10-60 parts by weight of Stigma Maydis, 10-60 parts by weight of Radix Trichosanthis, 6-30 parts by weight of Radix Scrophulariae, 10-60 parts by weight of Radix et Rhizoma Salviae Miltiorrhizae, and 10-50 parts by weight of Fructus Crataegi Preparata. In the TCM composition provided by the present disclosure, all medicinal materials are synergistic to achieve the effects of clearing heat, drying dampness, fortifying the spleen, dispersing blood stasis, dispersing accumulations, lowering lipids, nourishing yin and moistening dryness.

A method of accelerating the production of nitric oxide (NO) can include co-administering a generator of H.sub.2 with a generator of nitric oxide (NO) as a formulation to a subject. The generator of H.sub.2 includes elemental magnesium metal powder and the generator of NO is a nitrate, while the formulation is also free of amino acids.

A method of accelerating the production of nitric oxide (NO) can include co-administering a generator of H.sub.2 with a generator of nitric oxide (NO) as a formulation to a subject. The generator of H.sub.2 includes elemental magnesium metal powder and the generator of NO is a nitrate, while the formulation is also free of amino acids.

Disclosed herein is a method for manufacturing a composition promoting bone density enhancement, the method including preparing a mixture of Angelica gigas, Cnidium officinale, Phlomis umbrosa, Astragalus membranceus, Amomi fructus, Citri unshius pericarpium, Drynariae rhizoma, Codonopsis pilosulae radix, frankincense, and myrrh, aging the mixture, drying the mixture and grinding the dried mixture into a powder, and extracting a liquid from the powder.

Disclosed herein is a method for manufacturing a composition promoting bone density enhancement, the method including preparing a mixture of Angelica gigas, Cnidium officinale, Phlomis umbrosa, Astragalus membranceus, Amomi fructus, Citri unshius pericarpium, Drynariae rhizoma, Codonopsis pilosulae radix, frankincense, and myrrh, aging the mixture, drying the mixture and grinding the dried mixture into a powder, and extracting a liquid from the powder.

The invention relates to a new orally administered composition, which in present embodiments is a standardized phytochemical formulation but other embodiments may contain designed molecules. This formulation is capable of suppressing inflammation in a variety of disease conditions having an underlying inflammatory component, including but not limited to cystic fibrosis, COPD, asthma, and pancreatitis. It is an objective of the invention to provide a non-toxic therapy, which exhibits anti-oxidant anti-inflammatory properties without deleterious side effects.

The invention relates to a new orally administered composition, which in present embodiments is a standardized phytochemical formulation but other embodiments may contain designed molecules. This formulation is capable of suppressing inflammation in a variety of disease conditions having an underlying inflammatory component, including but not limited to cystic fibrosis, COPD, asthma, and pancreatitis. It is an objective of the invention to provide a non-toxic therapy, which exhibits anti-oxidant anti-inflammatory properties without deleterious side effects.